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Abstract
The increasing characterization of childhood acute lymphoblastic leukemia (ALL) has led to the 
identification of multiple molecular targets, but have yet to translate into more effective targeted 
therapies, particularly for high-risk, relapsed T-cell ALL. Searching for master regulators 
controlling multiple signaling pathways in T-ALL, we investigated the multi-functional protein 
redox factor-1 (Ref-1/APE1), which acts as a signaling “node” by exerting redox regulatory 
control of transcription factors important in leukemia. Leukemia patients’ transcriptome databases 
showed increased expression in T-ALL of Ref-1 and other genes of the Ref-1/SET interactome. 
Validation studies demonstrated that Ref-1 is expressed in high-risk leukemia T-cells, including in 
patient biopsies. Ref-1 redox function is active in leukemia T-cells, regulating the Ref-1 target NF-
κB, and inhibited by the redox-selective Ref-1 inhibitor E3330. Ref-1 expression is not regulated 
by Notch signaling, but is upregulated by glucocorticoid treatment. E3330 disrupted Ref-1 redox 
activity in functional studies and resulted in marked inhibition of leukemia cell viability, including 
T-ALL lines representing different genotypes and risk groups. Potent leukemia cell inhibition was 
seen in primary cells from ALL patients, relapsed and glucocorticoid-resistant T-ALL cells, and 
cells from a murine model of Notch-induced leukemia. Ref-1 redox inhibition triggered leukemia 
cell apoptosis and down-regulation of survival genes regulated by Ref-1 targets. For the first time, 
this work identifies Ref-1 as a novel molecular effector in T-ALL and demonstrates that Ref-1 
redox inhibition results in potent inhibition of leukemia T-cells, including relapsed T-ALL. These 
data also support E3330 as a specific Ref-1 small molecule inhibitor for leukemia.
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INTRODUCTION
Clinical studies using selective inhibitors of signaling molecules support the notion that, in 
most cancers, effective, curative therapeutic strategies require the concurrent disruption of 
multiple molecular targets or pathways (1, 2). Accordingly, the focus of targeted therapies is 
shifting to the identification of combinations of signaling inhibitors that optimally promote 
tumor cytotoxicity and overcome drug resistance on defined cancers, while preventing the 
emergence of tumor variants that may lead to cancer recurrence. In this context, the clinical 
development of drugs that disrupt master molecular regulators controlling the activity of 
multiple non-recurrent signaling pathways or transcription programs has great potential.
Ref-1 (redox factor-1; AP endonuclease 1, APE1; APEX1) is a multifunctional protein 
acting as a unique nuclear reduction-oxidation (redox) factor and a DNA repair 
endonuclease (3). In contrast to general reduction-oxidation systems, Ref-1 directly reduces 
cysteine residues in the DNA binding and activation domains of target transcription factors 
(TFs) (4), thus controlling their binding to target promoter sequences and their downstream 
transcriptional programs (3, 5–7). The redox targets of Ref-1 include NF-κB, AP-1, STAT3, 
p53, HIF-1 and other TFs (6, 8–10) that have been shown to play critical roles in 
tumorigenesis, cancer cell survival, proliferation, drug resistance and other functions. In 
solid tumors, increased expression of Ref-1 has been associated with drug-resistance and 
poor prognosis (6). Blockade of Ref-1 by E3330 (also called APX3330), a small molecule 
inhibitor that specifically recognizes the redox function of Ref-1, (11, 12) results in 
significant reduction or abrogation of the transcriptional activity of NF-κB, AP-1, and HIF-1 
(5, 7), and inhibition of tumor cell functions (5, 8, 10). This compound has IND approval 
and will enter Phase 1 clinical trials this year.
Despite successes in the treatment of pediatric T-cell acute lymphoblastic leukemia (ALL), 
leukemia relapse, refractory disease and induction failure continue to pose significant 
therapeutic challenges (13–16). In adult T-ALL, current therapies are much less effective, 
with high relapse rates and poor outcomes. Marked progress in the molecular 
characterization of T-cell ALL raised the prospect of a new generation of more efficient, 
selective therapies, particularly for high-risk and relapsed patients. This included the 
targeting of Notch signaling, which seems to function as an oncogenic driver in the majority 
of T-ALL (17–19). However, clinical trials with Notch pathway inhibitors showed limited 
efficacy and were hampered by significant toxicities, and studies showed that presence of 
Notch mutations is not associated with poor prognosis and that those patients may be in fact 
more responsive to conventional therapies (20). Other signaling effectors or pathways were 
identified as potential therapeutic targets for pediatric T-ALL, including PI3K/Akt, mTOR/
TORC1, NF-κB, Gfi-1, CXCL12/CXCR4 and others (21–25). Inhibitory compounds 
targeting these pathways are in preclinical development or in clinical studies, but the use of 
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signaling antagonists has yet to lead to transformative clinical successes in ALL patients. 
Therefore, the need remains for more effective, less toxic targeted therapies for high-risk, 
refractory and relapsed T-cell ALL.
In search for master molecular regulators of transcriptional programs in T-cell ALL, we 
investigated the potential role of Ref-1, as it exerts redox control of multiple transcription 
factors, including the leukemia-associated NF-κB, AP-1 and p53. We observed that Ref-1 is 
expressed in T-ALL specimens and cell lines, and that its redox function is active in 
leukemia T-cells. Blockade of Ref-1 by the redox-specific inhibitor E3330 resulted in potent 
inhibition of viability of leukemia T-cells, including primary cells, relapsed and 
chemotherapy-resistant cells, and cells from a mouse model of T-ALL. Ref-1 redox 
inhibition promoted leukemia cell apoptosis, which was associated with down-regulation of 
pro-survival genes. Although some studies have addressed the potential role of general redox 
systems (thioredoxin) in ALL (26), they have not led to clinical interventions and lack the 
target-selectivity of the Ref-1 redox function. Overall, our results demonstrate a role for 
Ref-1 in the regulation of multiple transcriptional programs in T-cell ALL, and suggest that 
disruption of Ref-1 redox function represents an efficient strategy to target leukemia T-cells, 
including high-risk, relapsed leukemias.
MATERIALS AND METHODS
Leukemia T-cells and Specimens
No clinical studies were performed in this work. Leukemia specimens were collected 
according with the protocol approved by the Indiana University Institutional Review Board. 
All leukemia specimens were unidentified, and no patient information was collected or used 
in this study. TAIL7, a human IL-7-dependent leukemia T-cell line that mimics the 
functional and molecular properties of primary T-ALL cells, was established in our 
laboratory in 2004 (27). TAIL7 cells were maintained in RPMI-1640 supplemented with 
10% FBS (RPMI-10) and IL-7 (10ng/ml; R&D Systems, Minneapolis, MN), and viable cells 
were separated on Ficoll every 7 days and recultured in fresh media. The immortalized T-
ALL cell lines Jurkat E6-1, MOLT-4, CCRF-CEM, Loucy, TALL-104 (IL-2-dependent) 
were obtained from ATCC, and SUP-T1 cells were obtained from a collaborator. All cell 
lines were obtained in 2014 and are validated for authenticity on a bi-annual basis. The 
Jurkat/Bcl2 and Jurkat/Neo are sublines derived from transfection of Jurkat cells 
respectively with a psFFV-neo expressing vector containing human BCL2 or empty vector, 
and were obtained from ATCC in 2014. TAIL7-ICN subline was generated by stable 
transduction of TAIL7 cells with constitutively-active Notch1 (ICN) construct, leading to 
persistence activation of Notch signaling and significant induction or upregulation of the 
expression of Notch target genes (Batista A, Cardoso AA, unpublished data) in 2014. 
TAIL7-DexaR is a subline resistance to high-dose Dexamethasone (up to 2μM) and was 
generated by exposure of TAIL7 cells to increasing doses of Dexamethasone in 2015. 
Primary T-ALL cells were obtained from diagnostic specimens of pediatric patients with 
high leukemia involvement (>90%) in 2015. After gradient centrifugation, cells were 
washed in RPMI-10.
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Animal model of Notch-induced T-ALL and xenograft model of human T-ALL
Animal models of leukemia (Notch-induced T-ALL; xenograft model of human T-ALL) 
were performed using protocols approved by the Indiana University School of Medicine 
IACUC. For the Notch-induced leukemia model, hematopoietic progenitor Lin- cells were 
purified from donor C57BL/6 mice (CD45.2+), and transduced with MSCV-ICN/GFP (ICN) 
viral particles (28). Equal numbers of transduced Lin-GFP+ICN+ cells (20,000/mice) were 
injected I.V. into lethally irradiated 8-wk old recipient BoyJ (CD45.1+) admixed with a 
radio-protective dose of BM cells (CD45.1+). This model has 100% penetrance, with 
leukemia progression correlating with increased WBC counts, circulating blasts and 
splenomegaly. Mice were bled weekly for WBC counts and quantification of leukemia cells, 
and were sacrificed at stage of terminal disease, at which they exhibit high content of blasts 
in PB, BM and spleen, with most leukemia cells being GFP+ CD4+ CD8+ (DP) T-cells. 
Cells were isolated from harvested femur bones and spleens, and processed for biochemical 
and functional studies.
For the xenograft human T-ALL model, TAIL7 cells (1×106) were transplanted i.v. into 
NOD/SCID or NSG mice (7–9wk old) (27, 29). Mice were bled weekly for presence of 
human blasts in the PB, by flow cytometry. Animals exhibiting >2% circulating human 
leukemia blasts were randomly allocated into experimental groups, and initiated treatment 
with Vincristine (i.p., 0.5mg/Kg, every 4 days for 3 weeks) or control vehicle. Mice were 
sacrificed at stage of terminal disease (very high leukemia cell content in BM), and leukemia 
cells were isolated from harvested femurs, and processed for functional studies.
Bioinformatics Analyses
Publicly available databases of transcriptome studies of pediatric ALL patients’ specimens 
were assessed and analyzed using Oncomine® 3.0 (30). Relative expression of Ref-1/
APEX1 or genes of the Ref-1 interactome was compared in T-ALL vs. BM from healthy 
donors, or in T-ALL vs. B-ALL. The Ref-1 interactome was defined based on the Human 
Protein Reference Database (HPRD, release 9; Institute of Bioinformatics, Johns Hopkins 
University) (31).
Immunoblotting
Cell lysates were prepared in RIPA lysis buffer system (Santa Cruz Biotechnology, Dallas, 
TX), as described (21, 22). All experiments with TAIL7 cells were performed using IL-7 
(10ng/ml). For studies of Ref-1 regulation by glucocorticoids, TAIL7 cells were incubated 
with Dexamethasone for the timepoints indicated. Equal amounts of protein (20–50mg/
sample) were resolved by SDS-PAGE, transferred onto nitrocellulose membranes, and 
immunoblotted with antibodies for Ref-1 (Novus Biologicals, Littleton, CO), or for Actin 
(Thermo Fisher Scientific, Waltham, MA) as loading control. Immunodetection was 
performed by incubation with HRP-conjugated anti-mouse IgG antibodies (EMD Millipore, 
Billerica, MA), followed by chemiluminescence developing using WesternBright Quantum 
Western blotting detection kit (Advansta, Menlo Park, CA). Determination of relative 
protein intensity was performed using Quantity One software (Bio-Rad, Hercules, CA).
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Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue samples from pediatric patients with T-ALL at the 
time of original diagnosis were used for immunohistochemistry. Immunoperoxidase staining 
was performed by an automated immunostainer (DAKO, Carpinteria, CA, USA) using a 
standard streptavidin–biotin–peroxidase complex technique and the Ref-1 Ab (1:200; Novus 
Biologicals). The primary antibody was followed by HRP-conjugated goat-anti-mouse Ab, 
with an irrelevant IgG2 antibody (Southern Biotech) used as isotype control. Images were 
acquired on an Olympus microscope using an Olympus DP71 camera.
Ref-1 Intracellular Staining and Flow Cytometry
Analysis of Ref-1 expression in leukemia T-cells was performed also using intracellular 
staining and flow cytometry. Briefly, leukemia cells were fixed in Cytofix/Cytoperm solution 
(BD Biosciences) for 30min, and then washed in Perm/Wash buffer (BD Biosciences) with 
3% BSA. Cells were incubated with anti-Ref-1 antibody (Novus Biologicals) at 1:125 
dilution for 2hrs, washed with Perm/Wash buffer, followed by incubation with PE-
conjugated or FITC-conjugated secondary antibodies (Southern Biotech, Birmingham, 
Alabama) at 1:500 dilution for 1.5hrs. Staining with fluorochrome-conjugated secondary 
antibody alone was used as negative control. Cells were acquired in a FACSCalibur flow 
cytometer (BD, Franklin Lakes, NJ), and data analyzed using FlowJo software (FlowJo 
LLC; Ashland, OR).
Ref-1 Redox Inhibitor E3330
E3330, also called APX3330, is a small molecule that inhibits the redox function of Ref-1 
by selectively recognizing the redox-active conformation of Ref-1 and blocking interaction 
with the downstream transcription factors. E3330 was synthesized by the University of 
Michigan Vahlteich Medicinal Chemistry Core Facility (Dr. Hollis Showalter), as previously 
described (7, 32). Analogs of E3330 (APX2007, APX2009 and APX2032) were synthesized 
by Cascade Custom Chemistry (Eugene, OR) as described (33). The synthesis steps include 
a common intermediate, iodolawsone (2-iodo-3-hydroxy-1,4 naphthoquinone which is 
reacted with methacrylic acid or 2-propylacrylic acid, along with oxalyl chloride and the 
corresponding amine, and with sodium methoxide in methanol to yield APX2007 [(2E)-2-
[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-
dimethylpentanamide], APX2009 [(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)methylidene]-N,N-diethylpentanamide], and APX2032 [(2E)-2-(3-methoxy-1,4-
dioxo-1,4-dihydronaphthalen-2-yl)-N,N,2-trimethylprop-2-enamide] (33).
Electrophoretic Mobility Shift Assay (EMSA)
Redox-EMSA were performed as previously described (34), with some modifications. 
Briefly, nuclear extracts were prepared from leukemia TAIL7 cells cultured in IL-7, as 
described (21, 22, 27). For the experiments assessing regulation of NF-kB DNA-binding by 
Ref-1, purified Ref-1 protein was reduced with 2mM DTT for 10min and diluted to a final 
amount of 4mg with 0.4mM DTT in PBS. Reduced Ref-1 was added to 15mg nuclear 
extract from leukemia cells. The final concentration of DTT in redox reactions was 0.02mM. 
A HEX-labeled double-stranded oligonucleotide DNA containing repeat consensus 
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sequences for NF-κB was used: 5′ - AGT TGA GGG GAC TTT CCC AGG C – 3′. For the 
competition experiment, increasing amount of unlabeled wild-type and mutant (5′-AGT 
TGA GGC GAC TTT CCC AGG C-3′) probe was added to the EMSA reaction with Hex-
labeled probe. For EMSA with Ref-1 redox inhibition, E3330 was preincubated with 
purified, reduced Ref-1 in EMSA reaction buffer for 30min, followed by addition of 3mg of 
TAIL7 cells’ nuclear extracts.
Gene Expression by Quantitative PCR
Quantitative PCR (qPCR) was used to quantify levels of defined mRNA transcripts in 
leukemia cells. RNA was extracted using the Qiagen RNeasy Mini kit (Qiagen; Valencia, 
CA), according to manufacturer’s instructions. cDNA was prepared using reserve 
transcriptase (Applied Biosystems, ABI; Foster City, CA), as described.(35) qPCR was 
performed using Taqman Gene Expression Assays for Ref-1, Survivin/BIRC5, and Bcl-xL 
expression (ABI), or SYBR® Green-based assay using the Brilliant II SYBR Green Kit 
(Agilent Technologies; Santa Clara, CA) for the other transcripts analyzed, in a 7900HT Fast 
Real-Time PCR System (ABI). Quantification was performed using the comparative Ct 
method, with GAPDH or 18S rRNA being used as reference, endogenous controls. In each 
experiment, assays were performed in duplicate or triplicate for each sample.
Viability Studies with E3330
Leukemia cell viability was determined using the CellTiter-Glo® ATP assay (Promega; 
Madison, WI), according to the manufacturer’s instructions. For experiments with E3330, 
leukemia cells were cultured with RPMI supplemented with 5% FBS (RPMI-5). TAIL7 cells 
were cultured with IL-7 (10ng/ml), and TALL-104 cells with IL-2 (20ng/mL; R&D 
Systems). Primary T-ALL cells were cultured with IL-7 plus IL-9 (10ng/ml; R&D Systems), 
and leukemia cells from the ICN-induced T-ALL model were cultured with IL-7 (10ng/mL), 
SCF (10ng/mL; R&D Systems) and FLT3L (10ng/mL; R&D Systems). All cultures were 
performed in triplicates, for the timepoints indicated. Plates were analyzed in a SpectraMax 
Gemini EM microplate reader (Molecular Devices; Sunnyvale, CA).
Apoptosis Assay
For apoptosis studies, leukemia cells were cultured with 25 or 40μM E3330, in RPMI-5. At 
the timepoints indicated, cells were resuspended in binding buffer, stained with FITC-
conjugated Annexin V (1μl/ml; BD-Biosciences) and Propidium Iodide (PI; 5μg/ml, 15min), 
and analyzed by flow cytometry.
Statistics
Differences between experimental study conditions were evaluated using the statistical tests 
indicated in the respective Figure Legends. Differences of means were considered 
statistically significant for p<0.05.
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RESULTS
The Ref-1 multi-function protein is expressed in leukemia T-cells
A data mining search for regulators that may control critical leukemia-associated 
transcriptional programs unveiled as a potential candidate Ref-1/APE1/APEX1, a multi-
functional protein known to regulate the transcriptional activity of NF-κB, AP-1, p53, 
STAT3, HIF-1, and other transcription factors (3, 5, 6, 10). Bioinformatics analyses of 
transcriptome datasets using Oncomine® showed that Ref-1/APEX1 transcripts are 
significantly elevated in the T-ALL patients in comparison to BM from normal donors 
(Figure 1A; p=1.30E-6; Andersson leukemia database) (36). Other molecules of the Ref-1/
APEX1 interactome (Supplementary Figure 1A) were found also to be increased in T-ALL 
specimens, including SET, CSNK2A1, NME1, TP53, and HDAC1 (Figure 1A; p values 
from 4E-4 to 1E-10). This expression pattern was confirmed in factor-dependent, patient-
derived leukemia TAIL7 cells using qPCR. Relative increased expression of Ref-1 
transcripts in T-cell ALL specimens was observed in other leukemia datasets (Oncomine®; 
Supplementary Figure 1B). Analyses of pediatric ALL specimens resistant to frontline 
chemotherapy drugs showed expression of Ref-1 transcripts, although with no statistically 
significant differences in comparison to drug-sensitive cases (Supplementary Figure 1C; ref. 
(37)). Next, we performed immunoblotting using leukemia T-cells representing distinct 
molecular genotypes, and including high-risk and relapsed T-cell ALL (Supplementary 
Table 1). Ref-1 protein was detected in all T-ALL cell lines tested, as well as in primary T-
ALL specimens (Figure 1B, 1C). Using a new flow cytometry assay to detect intracellular 
Ref-1, we confirmed marked expression of Ref-1 protein in all T-ALL lines tested 
(Supplementary Figure 2A). Importantly, immunohistochemistry analyses of biopsies from 
patients diagnosed with T-ALL confirmed expression of Ref-1 in leukemia cells (Figure 1D; 
two representative cases shown). We investigated the expression of Ref-1 in leukemia cells 
from a mouse model of T-ALL. In this model, transplantation of donor hematopoietic stem/
progenitor cells (HSPC) transduced with constitutively active, oncogenic Notch1 leads to the 
development of a malignancy in recipient mice that recapitulates human T-ALL (28, 38, 39). 
Immunoblotting using BM cells from mice with terminal leukemia (more than 95% 
leukemia cell content) showed high expression of Ref-1 protein (Figure 1E), which was 
confirmed in circulating leukemia cells (identified as expressing GFP, positivity for donor 
CD45.2 and CD4+ CD8+ phenotype) using intracellular staining and flow cytometry (Figure 
1F). These results are in congruence with those found in databases demonstrating a low level 
of Ref-1 in normal BM cells, and higher in leukemic cells (Figure 1A).
Ref-1 redox function and regulation in leukemia T-cells
To investigate the activity of Ref-1 redox in leukemia T-cells, we performed redox-EMSA 
assays in TAIL7 cells, assessing the DNA binding of the transcription factor NF-κB, a 
known redox target of Ref-1 and an important transcriptional effector in T-cell ALL (23, 24, 
40). First, we performed a competitive EMSA experiment using excess cold probe (WT) to 
block NF-κB DNA binding or a NF-κB binding-defective probe (mutant), as control. Excess 
WT competitor probe resulted in marked inhibition of the NF-κB binding to DNA in the 
presence of reduced Ref-1 protein (over 90%), which was not observed using the mutated, 
binding-defective probe (Figure 2A). Second, we performed EMSA assays for NF-κB 
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binding in the presence of the Ref-1 inhibitor E3330, which has been shown to inhibit 
selectively the redox activity of Ref-1, without affecting its DNA repair function (7). As 
shown in Figure 2B, incubation of reduced Ref-1 with increasing amounts of E3330 resulted 
in a dose-dependent inhibition of binding to NF-κB consensus sequence, in nuclear extracts 
from leukemia TAIL7 cells. Quantification showed that E3330 inhibits NF-κB binding with 
an IC50 of 37.9 ± 2.6μM (Figure 2C). Overall, these studies demonstrate that the Ref-1 
redox function is preserved in leukemia T-cells, controlling the binding of NF-κB to DNA 
target sequences.
Subsequently, we performed experiments to analyze the potential regulation of Ref-1 protein 
expression in leukemia T-cells. The majority of T-ALL patients exhibit genomic alterations 
activating the Notch pathway, and multiple studies showed that Notch signaling an important 
role in the biology of primary T-ALL cells (18, 19). To investigate whether increased Notch 
signaling impacts on Ref-1 expression, we performed immunoblotting in a TAIL7 cell 
subline transduced to overexpress an activated form of Notch1 (TAIL7-ICN; exhibits 
increased Notch activation and expression of Notch target genes; Batista A, Cardoso AA, 
unpublished data) in comparison to parental TAIL7 cells. We observed that increased Notch 
signaling does not affect the levels of Ref-1 protein in leukemia T-cells (Figure 3A), and no 
changes were observed in Ref-1 transcript levels. In addition, analysis of a public dataset 
assessing transcriptome changes in T-ALL cell lines following blockade of Notch signaling 
via gamma-secretase inhibition (compound E), showed no effects on Ref-1/APEX1 mRNA 
relative expression (Supplementary Figure 3A; data collected from Palomero et al. using 
Oncomine; ref. (41)).
Refractory, relapsed leukemia remains a significant problem in T-ALL, and resistance to 
glucocorticoids is a predictor of poor prognosis in pediatric ALL, including T-ALL (42). 
Therefore, we investigated whether glucocorticoid exposure affected Ref-1 expression. 
Dexamethasone treatment of TAIL7 cells resulted in upregulation of Ref-1 protein, which 
was observed as early as 6 hrs, remaining elevated at 7 days post-treatment (Figure 3B–C). 
Flow cytometry analysis of intracellular Ref-1 following stimulation with Dexamethasone 
confirmed upregulation of Ref-1 protein expression in factor-dependent TAIL7 cells, in a 
dose-dependent manner (Figure 3D). qPCR analysis showed that Dexamethasone treatment 
does affect the levels of Ref-1 transcripts in leukemia cells, but only at the 48 hour time 
point, and the level of elevated expression, while statistically significant is only a 0.25 fold 
increase and not of major biological relevance (Supplementary Figure 3B), suggesting that 
the effect of glucocorticoids on Ref-1 expression involves more of a protein increase or 
stabilization of Ref-1 rather than a transcriptional regulation mechanism. Overall, these 
studies suggest that Ref-1 expression in leukemia T-cells is not regulated by the Notch 
signaling, but protein levels can be modulated by exposure to glucocorticoids.
Selective blockade of Ref-1 redox potently inhibit leukemia T-cells, including drug-
resistant, relapsed T-ALL cells
Functional studies were performed to determine the impact of Ref-1 blockade in leukemia T-
cells, by using E3330, a highly selective compound that recognizes a redox-active Ref-1 
protein (11, 12, 43). First, we evaluated the effect of E3330 on leukemia cell viability, using 
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the T-ALL cell lines described above (Supplementary Table 1). Treatment with E3330 
resulted in potent, dose dependent inhibition of the survival of TAIL7 cells (Figure 4A), with 
an IC50 of around 22.5 μM (Figure 4K). Importantly, as shown in Figure 4B–G, E3330 
showed comparable inhibitory effects in leukemia cell lines representing distinct genotypes, 
including high-risk ETP leukemia (as LOUCY), or derived from patients in leukemia 
relapse. Although some variability was seen between experiments, the IC50s calculated for 
the E3330 activity in the different T-ALL lines were within a limited dose range (from 20.5 
to 26.1μM; Figure 4K), which correspond to clinically achievable concentrations (5). We 
also evaluated the effect of second generation Ref-1 inhibitors APX2007, APX2009 and 
APX2032 on leukemia cell viability on TAIL7 cell (Figure 4H–J). The IC50s ranged from 
2.5 to 5.0 μM for the three compounds and is consistent with our evaluations of these agents, 
particularly APX2009, demonstrating 5–10 increased efficacy (33).
We next evaluated the activity of Ref-1 redox blockade by E3330 in primary cells from 
leukemia patients, using the ATP assay. As seen in Figure 5A, E3330 markedly inhibited 
leukemia T-cell viability in all cases tested, including a specimen from a T-ALL relapse 
patient (Pt_B). We then investigated the efficacy of E3330 in leukemia cells obtained from 
mice exhibiting terminal ICN-induced T-cell leukemia, as described above (38, 39). Cells 
were isolated from the BM and spleen of mice with terminal leukemia, which is 
characterized by massive splenomegaly, hepatomegaly, and high leukemia cell content in 
these organs. As shown in Figure 5B, murine leukemia T-cells were sensitive to E3330 
treatment, with significant inhibition of cell survival even in the presence of stimulatory 
cytokines (IL-7, SCF, FLT3L). Since Ref-1 has been associated with drug resistance (6) and 
we observed that glucocorticoid exposure upregulates Ref-1 expression, we investigated the 
activity of Ref-1 redox blockade by E3330 in leukemia TAIL7 cells selected for resistance to 
high-dose Dexamethasone (TAIL7-DexaR), which express increased levels of Ref-1 protein 
(Figure 3B; Supplementary Figure 3C). Inhibition of Ref-1 redox resulted in marked 
inhibition of TAIL7-DexaR cells (Figure 5C), albeit with small reduction in efficacy in 
comparison to parental TAIL7 cells (which are moderately resistant to Dexamethasone). 
Additionally, we investigated the potency of E3330 in inhibiting leukemia T-cells from a 
xenograft model of leukemia relapse post-chemotherapy (Figure 5D). In this model, mice 
transplanted with TAIL7 cells were treated with Vincristine at evidence of circulating 
leukemia, which resulted in increased overall survival (Supplementary Data Figure 3D; 
p<0.001); however, following disease remission, leukemia recurrence is observed in all 
animals, which developed terminal leukemia around d57 to d61, thus recapitulating human 
T-cell ALL relapse. As shown in Supplementary Data Figure 3D leukemia T-cells harvested 
from mice in leukemia relapse post-Vincristine therapy retained their sensitivity to Ref-1 
redox blockade, as shown by their marked inhibition by E3330 treatment(Figure 5D). These 
studies demonstrate that leukemia TAIL7 cells resistant to frontline drugs in in vivo 
therapeutic studies retain their sensitivity to Ref-1 redox inhibition, and support the use of 
animal models of chemotherapy for the pre-clinical evaluation of more potent, selective 
inhibitors of Ref-1 redox activity.
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Blockade of Ref-1 redox function promotes leukemia cell apoptosis
To define the mechanism by which Ref-1 blockade exerts its inhibitory effects on leukemia 
T-cells, we investigated the impact of E3330 treatment on leukemia cell viability. Using 
TAIL7 cells as a model, cell death was assessed using the Annexin V/PI apoptosis assay. As 
shown in Figure 6A, E3330 treatment result in marked increase in leukemia cell death, in a 
dose dependent manner, with massive apoptosis at d4 and d5 for 40μM dose. Next, we 
evaluated the effect of E3330 treatment on the expression of the pro-survival genes Bcl-xL 
and Survivin/BIRC5, which have been implicated in ALL biology and are known 
transcriptional targets of Ref-1-regulated TFs. We observed that treatment with E3330 
results in significant inhibition in the expression of Survivin and Bcl-xL (Figure 6B; 
p<0.0001 and p=0.0001, respectively). Finally, since Bcl-2 functions as a survival effector in 
ALL cells (29, 44) and its transcription is also regulated by Ref-1-sensitive TFs as NF-κB 
(45), we evaluated whether Bcl-2 overexpression impacted on the inhibitory effects of 
E3330 in leukemia T-cells. Here, Jurkat/Bcl-2 cells transfected with a psFFV-neo expressing 
vector containing human Bcl-2 were compared to control Jurkat/Neo cells containing the 
empty vector; these two sublines expressed comparable levels of Ref-1 protein. As shown in 
Figure 6C, Jurkat/Bcl2 cells are partially rescued from the inhibitory effects of E3330 in 
comparison to the control Jurkat/Neo cells (p<0.01). Taken together, these studies show that 
blockade of Ref-1 redox triggers apoptosis of leukemia T-cells, which is associated with 
downregulation the transcription of the pro-survival genes Bcl-xL and Survivin, and that 
overexpression of Bcl-2 partially protects leukemia T-cells from the inhibitory effects of 
E3330.
DISCUSSION
The pursuit for potential multi-pathway regulators in pediatric T-cell ALL led us to the 
identification of Ref-1 redox as a novel molecular effector in this malignancy, including for 
high-risk and refractory, relapsed disease. Here we demonstrate that leukemia T-cells 
express functional Ref-1 protein, which regulates through its redox activity the binding of 
TFs to promoters (e.g. NF-κB), and the transcription of critical target genes (as Survivin and 
Bcl-xL). Blockade of Ref-1 signaling activity by E3330 results in potent inhibition of 
proliferation and survival of T-ALL cells, by promoting leukemia cell apoptosis and 
downregulation of pro-survival genes. To the best of our knowledge, this represents the first 
demonstration that Ref-1 redox plays a significant functional role in T-cell ALL, supporting 
Ref-1 as a potential new target for this malignancy.
Ref-1 functions as a redox signaling factor as well as having endonuclease activity repairing 
DNA lesions induced by oxidative and alkylating agents in the DNA base excision repair 
(BER) pathway. In its redox signaling function, Ref-1 exerts a selective transcriptional 
control on a restricted number of TFs containing cysteine residues in their DNA-binding 
domains, which are reduced in a specific manner, requiring the Cys-65 residue of human 
Ref-1, along with Cys-93 and Cys-99 (4, 11, 12). Thus, selective blockade of Ref-1 redox 
function represents a strategy to target critical leukemia-associated TFs and their 
downstream transcriptional targets, including pro-survival, mitogenic and cell cycle 
progression effectors. In particular, Ref-1 exerts redox control of: i) NF-κB, which is 
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activated by Notch signaling in T-ALL, and regulates the transcription of anti-apoptotic 
genes (23, 24); ii) p53, which has been associated with the pro-apoptotic activity of 
signaling antagonists effectively inhibiting T-ALL cells (22, 25), and; iii) AP-1, which is 
constitutively activated in leukemia cells from patients with HTLV-I induced adult T-cell 
leukemia (46). Also, we have determined that Ref-1 redox-regulated TF STAT3 is essential 
for T-cell leukemogenesis, and that disruption of STAT3 potently inhibits T-ALL cell 
survival (Ding, Cardoso; manuscript in preparation). Therefore, blockade of Ref-1 redox in 
T-ALL cells seems to impact on multiple pathways playing important roles in leukemia cell 
biology, permitting more robust anti-leukemia responses and potentially reducing the risk of 
selection of resistant, non-responsive tumor variants.
General reduction-oxidation systems that help maintain intracellular homeostasis by 
scavenging reactive oxygen species (ROS) (47, 48) may affect transcriptional programs by 
globally reducing TFs, in a non-selective manner. Changes in redox biology are often 
observed in cancer, and studies showed that oncogenic events can influence redox 
homeostasis, altering the expression/activity of anti-oxidant pathways (49, 50). Thus, 
therapeutic approaches have been proposed to disrupt the oxidative state of cancer cells and 
to increase ROS levels towards promoting cell death. Several frontline therapeutic agents 
that produce ROS are used in the clinic, including chemotherapy agents employed in ALL 
treatment (as Vincristine, anthracyclines, cytarabine) and targeted molecular antagonists (as 
HDAC inhibitors, proteasome inhibitors). However, the cells’ oxidative state is dictated by a 
delicate balance between pro- and anti-oxidant pathways, and the effect of ROS-producing 
agents on cancer cells is influenced by anti-oxidant enzyme systems (as HMOX1, GSH/
glutathione, thioredoxin/Trx, peroxiredoxin, SOD/superoxide dismutase), which can affect 
therapeutic efficacy and drug resistance (49). Multiple studies showed that leukemia cells 
exhibit altered redox biology, with alterations in the expression and activity of ROS and anti-
oxidant effectors, and these systems have been implicated in leukemogenesis. In ALL, it has 
been reported that the levels of GSH, Trx and peroxiredoxin are increased, whereas SOD is 
reduced (26, 51–53). In particular, thioredoxin is increased in T-ALL specimens, namely in 
cases with high WBC counts, and it has been suggested that selective inhibition of Trx may 
represent an effective strategy to overcome drug resistance and to sensitize leukemia T-cells 
to conventional chemotherapy drugs (26). Interestingly, it has been shown that Trx can 
reduce and thereby activate Ref-1 (54), which could increase the transcriptional activity of 
Ref-1-controlled TFs. Targeting of general oxidative systems such as Trx poses challenges 
of target selectivity, and no strategies specifically disrupting general redox systems have 
translated yet into more efficient therapies for ALL. Our approach is dramatically different, 
targeting specific protein-protein redox signaling and effectively blocking TF function.
E3330 is a small molecule that was initially described as an inhibitor of NF-κB activation 
(55), and then correctly identified as a specific inhibitor of Ref-1 redox function that blocked 
NF-κB activation (43). E3330 recognizes a redox active conformation of Ref-1 and 
inhibiting its redox activity (11). Although multiple signaling pathways are modulated by 
Ref-1 redox function, no unacceptable toxicity has been observed in in vivo preclinical 
studies using E3330 (Ref. (5), and FDA IND submission), as well as in human clinical trials 
for a non-cancer indication performed previously by Eisai Co.
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Little is known on the stimuli and molecular mechanisms regulating the expression of Ref-1, 
or regulating its redox activity. Ref-1 regulates the expression of cytokines, such as IL-6, 
IL-8, IL-12 and other inflammatory mediators that are downstream targets of TFs under the 
redox control of Ref-1 (56, 57). However, it is not known whether cytokines can influence 
the expression of Ref-1 protein in tumor cells. We have found that Ref-1 levels are not 
affected by IL-7 stimulation in leukemia cells, or by IL-6 treatment of pancreatic cancer 
cells (10, 58). As shown in this study, Ref-1 expression in leukemia cells does not seem to 
be directly regulated by Notch signaling, and it remains to be determined which 
mechanism(s) mediate the increased levels of Ref-1 transcripts seen in T-ALL specimens. 
Increased expression of Ref-1 has been associated with drug resistance (6), and it has been 
reported that patients with high Ref-1 protein levels show increased resistance to cisplatin 
treatment and other chemotherapeutic agents (59). Here, we show that Ref-1 protein levels 
are upregulated by glucocorticoid treatment. It has been reported that Ref-1 protein can be 
regulated by MDM2 and there is evidence of a molecular link between glucocorticoid 
receptor signaling and MDM2 activity (60); future studies are necessary to determine 
whether the effect of glucocorticoids seen in T-ALL cells involves MDM2-mediated 
regulation of Ref-1 ubiquitination and degradation. Finally, it has been reported that the 
redox activity of Ref-1 is augmented by its phosphorylation by the casein kinase CK2, 
enhancing the DNA binding of AP-1 to target genes (61). This is noteworthy as we have 
shown that CK2 activity is increased in T-ALL, and selective blockade of CK2 results in 
inhibition of leukemia cell survival (62). Although these effects have been related to CK2 
activity in the regulation of the PTEN/PI3K axis, it would be interesting to assess in future 
studies whether the inhibitory effects of CK2 blockade in T-ALL are mediated through 
inhibition of Ref-1 redox function.
In summary, we demonstrate that the redox factor Ref-1 plays an important regulatory role 
in the biology of T-cell ALL. This represents the first approach targeting T-ALL cells by the 
selective blockade of a key regulator of redox-controlled transcription programs, affecting 
multiple signaling pathways. This work supports Ref-1 redox function as a novel molecular 
target and “node” in leukemia T-cells, and the potential translation into clinical trials for 
refractory, relapsed T-ALL using high-affinity Ref-1 redox inhibitors. Initial steps in this 
direction are being taken with the beginning of a Phase 1 trial using E3330 (APX3330) in 
human cancer patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ref-1 expression in leukemia T-cells
A) Heatmap displaying relative expression levels of transcripts for Ref-1/APEX1 and Ref-1-
interacting proteins in patients with T-cell ALL and BM from normal donors; data obtained 
the Andresson Leukemia database, and analysis performed in Oncomine 3.0, using the Ref-1 
interactome as defined by the Human Protein Reference Database (HPRD). B) 
Immunoblotting for Ref-1 in leukemia T-cell lines and primary cells from a T-ALL patient 
(Pt#3). Actin was used as loading control. C) Relative expression of Ref-1 protein in T-ALL 
cells by immunoblotting, determined by densitometry, and normalized to Actin expression 
levels. D) Immunohistochemistry using Ref-1 Ab in biopsies from two patients diagnosed 
with T-ALL. E) Immunoblotting for Ref-1 in leukemia cells harvested from the BM of mice 
exhibiting terminal Notch-induced T-cell ALL and control normal mice BM cells, Actin was 
used as loading control. F) Intracellular staining with Ref-1 Ab of leukemia cells from mice 
carrying Notch-induced T-ALL; at least 10,000 events were acquired by flow cytometry and 
analyzed using FlowJo, with leukemia cells gated based on GFP positivity. Dark gray 
histogram indicates Ref-1 staining and light gray histogram indicates isotope IgG negative 
control.
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Figure 2. Ref-1 redox controls NF-κB DNA binding in leukemia T-cells
A) Competitive EMSA for NF-κB using nuclear extracts from TAIL7 cells in the presence 
of WT or NF-κB-binding-defective cold probe (25-, 50- or 75-fold). B) NF-κB redox-
EMSA in extracts from TAIL7 cells treated with increasing doses of E3330. DTT final dose 
was 0.02mM. C). Densitometry quantification of effect of E3330 on NF-κB DNA binding in 
TAIL7 cells; data shown as mean ± SEM from two independent experiments. *p<0.05, 
**p<0.01, using T-test.
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Figure 3. Ref-1 expression in leukemia cells is not influenced by Notch signaling, but is 
upregulated by Dexamethasone
A) Immunoblotting of Ref-1 expression in leukemia TAIL7 cells and the TAIL7-ICN 
subline, which overexpresses ICN and exhibit increased expression of Notch target genes; 
three independent replicates for each condition. Actin was used as loading control. B) 
Immunoblotting of Ref-1 expression in TAIL7 cells treated with Dexamethasone (200nM) 
for the periods indicated; TAIL7-DexaR is a subline that is resistant to high-dose 
Dexamethasone, three independent replicates for each condition, Actin was used as loading 
control. C) Relative expression of Ref-1 protein TAIL7 cells treated with Dexamethasone 
(200nM) for the periods indicated, by immunoblotting; determined by densitometry, and 
normalized to Actin expression levels. Data shown as mean ± SEM. *p<0.05, ** p<0.01 
Mann-Whitney test. D) Intracellular staining with Ref-1 Ab in TAIL7 cells treated with 
increasing doses of Dexamethasone (125, 250, 500nM); at least 8,000 events were acquired 
by flow cytometry and analyzed using FlowJo. Ref-1 histograms are depicted in pink 
(125nM), orange (250nM) and red (500nM), and light gray histogram indicates isotype 
negative control.
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Figure 4. Blockade of Ref-1 redox by E3330 or second generation Ref-1 inhibitors markedly 
inhibits human T-ALL cell lines
A) ATP-based viability assay using cytokine-dependent TAIL7 cells, in the presence of 
increasing doses of the Ref-1 redox inhibitor E3330 (5 to 50μM); TAIL7 cells were cultured 
in the presence of IL-7 (10ng/mL), and analyses performed at 96hrs. Data shown as mean ± 
SEM, from 9 independent experiments. *p<0.05, **p<0.01, ***p<0.001, using T-test. B-G) 
ATP viability assessing effect of E3330 on various human leukemia T-ALL lines, 
representing different genotypes and risk groups. Data shown as mean ± SEM, from 
respectively 5 (Sup-T1), 4 (Jurkat, MOLT-4, CCRF-CEM, Loucy) or 2 (TALL-104) 
independent experiments. H-J) ATP viability assessing effect of second generation Ref-1 
inhibitors on TAIL7 cell line. Data shown as mean ± SEM, from four independent 
experiments *p<0.05, **p<0.01, ***p<0.001, using T-test. K) IC50 graph of E3330 in cell 
lines tested.
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Figure 5. E3330 is a potent inhibitor of leukemia T-cells, including refractory, relapsed T-ALL
A) Effect of E3330 on primary leukemia cells from T-ALL patients, using the ATP assay. 
Cells were cultured in the presence of IL-7 (10ng/mL) and IL-9 (10ng/mL), and analyses 
performed at 96hrs. *p<0.05, **p<0.01, ***p<0.001, using T-test. B) Effect of E3330 on 
BM or spleen (Spl) leukemia cells from mice carrying Notch-induced T-ALL, using the ATP 
assay. Cells were cultured with IL-7, SCF, and FLT3L, and analyses performed at 96h. Data 
shown as mean ± SD, n=6; *p<0.05, ***p<0.001 for BM and Spl, using 1-way ANOVA. C) 
ATP viability assay assessing effect of E3330 on TAIL7 cells resistant to high-dose 
Dexamethasone (TAIL7-DexaR) in comparison to parental TAIL7 cells; cells were cultured 
with IL-7, and analyzed at 96 hrs. Data shown as mean ± SEM, from three independent 
experiments. *p<0.05, **p<0.01, ***p<0.001, using T-test D) Cell viability assessing the 
effect of E3330 on leukemia cells from xenograft mice exhibiting relapse T-ALL, following 
remission induced by Vincristine therapy. Cells were cultured with IL-7, and analyzed at 
96hrs using the ATP assay. Data shown as mean ± SD, n=4; *p<0.05, **p<0.01, 
***p<0.001, using 1-way ANOVA.
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Figure 6. Ref-1 redox signaling inhibition by E3330 promotes apoptosis of leukemia T-cells, 
inhibiting expression of anti-apoptotic genes
A) Cell death as defined by the Annexin V/PI assay in leukemia TAIL7 cells treated with 
E3330 at the doses indicated. Data is shown as mean ± SD. *p<0.05, **p<0.01, using T-test. 
B) qPCR for mRNA expression of Survivin/BIRC5, Bcl-xL in TAIL7 cells treated with 
E3330, at the doses indicated. GAPDH was used as endogenous control, and the assays 
performed using TaqMan probes. Data shown as mean ± SEM, n=4; *p<0.05, **p<0.01, 
using 1-way ANOVA. C) ATP viability assay with E3330 in Jurkat cells overexpressing 
Bcl-2 (Jurkat/Bcl2) in comparison to control, vector-expressing cells (Jurkat/Neo); analyses 
at 96hrs. Data shown as mean ± SEM, from 4 independent experiments; *p<0.05, **p<0.01, 
for Jurkat/Bcl2 vs. Jurkat/Neo, using 2-way ANOVA.
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